Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838827 | 1.00 | MIF (0.46) | MIFMEN1KMT2ATDP1POLB | |
| SCHEMBL2589303 | 1.00 | MIF (0.46) | MIFMEN1KMT2ATDP1POLB | |
| SCHEMBL8306398 | 0.92 | MIF (0.50) | MIFMEN1KMT2ATDP1POLB | |
| SCHEMBL8470843 | 0.92 | MIF (0.50) | MIFMEN1KMT2ATDP1POLB | |
| SCHEMBL13499995 | 0.89 | MIF (0.45) | MIFTDP1ALDH1A1FAAHLMNA | |
| SCHEMBL349917 | 0.89 | MIF (0.58) | MIFTDP1FAAHCA2 | |
| SCHEMBL349916 | 0.89 | MIF (0.58) | MIFTDP1FAAHCA2 | |
| SCHEMBL20848265 | 0.88 | MIF (0.44) | MIFMEN1KMT2ATDP1POLB | |
| SCHEMBL22286019 | 0.85 | MIF (0.43) | MIFMEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL22286018 | 0.85 | MIF (0.43) | MIFMEN1KMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326728-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-10-23 | — | — | US | disclosed |
| EP-4551562-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2025-05-14 | — | — | EP | disclosed |
| CN-119487013-A | Benzothiepine (di) nitrogen cycloheptatriene compounds Compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12187690-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2025-01-07 | — | — | US | disclosed |
| CN-118852054-A | Benzothiadiazepines cycloheptatriene compounds Compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024184924-A1 | \"AN IMPROVED PROCESS FOR THE PREPARATION OF ODEVIXIBAT AND ITS CRYSTALLINE FORMS\ | RK PHARMA INC (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-113677398-B | Benzothiadiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| WO-2020161217-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247769-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2563122-A1 | CHEMICAL COMPOUNDS | Glaxosmithkline LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011137135-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | PHARMACIA CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | G.D. SEARLE LLC | 2002-12-05 | — | — | US | disclosed |
| WO-2002008211-A2 | BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | G.D. SEARLE, LLC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247769-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | MIF 3706/4885MEN1 4640/4885KMT2A 1642/4885 |
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | SLC10A1, ABCB11, SLC10A2 | MIF 4685/4885MEN1 2842/4885KMT2A 1686/4885 |
| US-20250326728-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | MIF 3706/4885MEN1 4640/4885KMT2A 1642/4885 |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | MIF 4476/4885MEN1 2349/4885KMT2A 1796/4885 |
| US-20130029938-A1 | Chemical Compounds | CYP11B1, GOT2, CYP11B2 | MIF 4339/4885MEN1 732/4885KMT2A 2624/4885 |
| US-12187690-B2 | Benzothiadiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | MIF 3706/4885MEN1 4640/4885KMT2A 1642/4885 |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | MIF 4512/4885MEN1 4086/4885KMT2A 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.